2Mackay F, Schneider P, Rennert P, et al. BAFF and APRIL: a tutorial on B-cell survival. Annu Rev Immunol, 2003;21:231 - 264.
3Kawasaki A, Tsuchiya N, Fukazawa T, et al. Analysis on the association of human BLYS ( BAFF, TNFSF13B ) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun, 2002 ;3 ( 7 ) : 424 - 429.
4Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol, 2007; 136 (2) : 309 -314.
5Mackay F, Browning JL. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol,2002 ;2(7) :465 -475.
6Moore PA, Belvedere O, Orr A, et al. BlyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science, 1999 ;285 ( 5425 ) :260 - 263.
7O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med, 2004;199(1) :91 -98.
8Enzler T, Bonizzi G, Silverman GJ, et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006;25 (3) :403 -415.
9Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthritis Rheum, 2001 ; 44 ( 6 ) : 1313 - 1319.
10Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R- Fc fusion protein in immune thrombocytopenia. Blood,2009:114 (26) :5362-5367.
